HER-2 Positive Breast Cancer Latest Advances

Find the Latest Research About HER-2 Positive Breast Cancer

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 700 publications

Corrigendum to "PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer" [Cancer Lett. 598 (2024) 217112].

Corrigendum to "PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer" [Cancer Lett. 598 (2024) 217112].

Journal: Cancer letters
Published: June 30, 2026

Retraction Note: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Retraction Note: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Journal: Nature communications
Published: June 29, 2026

Development of a Doxorubicin Resistance Model in HER2- and HER2+ Breast Cancer to Analyze Potential Therapy Targets and Drug Delivery Methods.

Development of a Doxorubicin Resistance Model in HER2- and HER2+ Breast Cancer to Analyze Potential Therapy Targets and Drug Delivery Methods.

Journal: Cells
Published: June 23, 2026

Circulating and Tissue MicroRNA Profiles Associated with Pathological Complete Response in HER2+ Breast Cancer: A Systematic Review.

Circulating and Tissue MicroRNA Profiles Associated with Pathological Complete Response in HER2+ Breast Cancer: A Systematic Review.

Journal: International journal of molecular sciences
Published: June 22, 2026

Plain language summary about how patients with HER2 positive breast cancer across Europe feel about their cancer, treatment, and future health and related implications for their treatment journey.

Plain language summary about how patients with HER2 positive breast cancer across Europe feel about their cancer, treatment, and future health and related implications for their treatment journey.

Journal: Future oncology (London, England)
Published: May 13, 2026

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies: case report.

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies: case report.

Journal: Frontiers in oncology
Published: April 26, 2026

Aryl Hydrocarbon Receptor Activation by Imidacloprid as a Promoter of HER2(+) Breast Cancer Progression: In silico, in vitro and in vivo studies.

Aryl Hydrocarbon Receptor Activation by Imidacloprid as a Promoter of HER2(+) Breast Cancer Progression: In silico, in vitro and in vivo studies.

Journal: Environmental research
Published: March 31, 2026

Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia.

Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia.

Journal: Current oncology (Toronto, Ont.)
Published: March 26, 2026

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Journal: BMJ (Clinical research ed.)
Published: March 16, 2026

A Retrospective Interventional Study Examining Whether Successful Replacement Therapy After a Confirmed Vitamin D Deficiency Correlates with Improved Disease-Free Survival in the Curative Intent Treatment of HER2+ Breast Cancer.

A Retrospective Interventional Study Examining Whether Successful Replacement Therapy After a Confirmed Vitamin D Deficiency Correlates with Improved Disease-Free Survival in the Curative Intent Treatment of HER2+ Breast Cancer.

Journal: Nutrients
Published: March 10, 2026

Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2+ breast cancer.

Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2+ breast cancer.

Journal: Toxicology in vitro : an international journal published in association with BIBRA
Published: February 04, 2026

Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.

Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.

Journal: Breast cancer (Dove Medical Press)
Published: January 27, 2026
Showing 1-12 of 700

Last Updated: 09/26/2026